Covid-19 has shown "an average efficacy of 70 percent" in trials.Commenting on the findings, Pascal Soriot, Chief Executive Officer, said: “Today marks an important milestone in our fight against the pandemic.
This vaccine’s efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency."The vaccine’s simple supply chain and our no-profit pledge and commitment to broad, equitable and timely access means it will be affordable and globally available, supplying hundreds of millions of doses on approval," Soriot further added.Professor Andrew Pollard, Chief Investigator of the Oxford Vaccine Trial at Oxford, said: “These findings show that we have an effective.